Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

The purpose of this study is to assess long-term safety and provide continued study
treatment access to eligible participants who are judged by the Investigator to benefit
from continued treatment with capmatinib monotherapy or in combination with other
treatments or with the combination treatment alone in a Novartis sponsored study This is an open-label, multi-center, rollover study to assess long-term safety in
participants who have completed a prior Novartis-sponsored study, that have fulfilled the
eligibility requirements and are judged by the Investigator to benefit from continued
treatment with capmatinib given as monotherapy or in combination with other treatments or
with the combination treatment alone.

There will be no screening period for this study. After providing informed consent, all
eligible participants will begin their treatment within the rollover study. Participants
should return to the study center for resupply of the study medication/s and for safety
assessment following the usual local practice. During a public health emergency as
declared by local or regional authorities (i.e. pandemic, epidemic or natural disaster)
that limits or prevents on-site study visits, alternative methods of providing continuing
care may be implemented by the Investigator as the situation dictates.

Participants will continue to be treated until they are no longer benefitting from the
study treatment in the opinion of the treating physician, develop unacceptable toxicities
that preclude further treatment with the study treatment, disease progression, withdrawal
of consent, discontinuation at the discretion of the Investigator, initiation of new
anticancer therapy, until the study treatment is commercially available and reimbursed
or/and available under any other local mechanism (such as compassionate use, named
patient program) for the appropriate indication and/or discontinuation for any other
reason. Participants receiving capmatinib as part of a combination therapy could continue
treatment only with capmatinib or with the combination treatment as single agent in case
one of the two compounds is permanently discontinued, if in the opinion of the treating
physician they are still benefitting from the treatment.

A patient will reach the end of rollover study when study treatment is permanently
discontinued and the end of treatment visit has been performed. All participants will be
followed up for safety for 30 days after the last dose of study treatment or until SAE is
resolved as required, whichever is later.

The study is expected to remain open for up to 10 years or until such time that all
enrolled participants no longer need treatment with study treatment(s) or Novartis
decides to stop the development program, whichever comes first.